Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

6.600 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2
...
26 27 28 29 30 31 32 33 Next >
MindMed Reports Q2 Earnings With Net Loss of $36M And Cash Balance Of $157M To Continue With Its Clinical Pipeline
The psychedelics-focused medicines company MindMed (NASDAQ: 
Via Benzinga
No Matter How the Pandemic Rolls, Mind Medicine Will Prevail
While MNMD stock is controversial due to its underlying psychedelic therapies, the broader narrative is exceptionally compelling. 
Via InvestorPlace
Which Psychedelic Drug Has The Most Commercial Potential?
As the Mental Health Crisis has become a mental health pandemic, clinical research on psychedelic drugs is showing that these substances are the best – and only – option to address this crisis. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2021
Upgrades Stephens & Co. upgraded the previous rating for Roku Inc (NASDAQ: 
Via Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
Exposures COVID-19
Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected
Last week in Psychedelics: 
Via Benzinga
Another Psychedelic Stock Debuts, As This One Sets Up In A Base
Field Trip Health dipped in its first day on the Nasdaq, making it the latest psychedelics company to hit a big U.S. exchange. 
Via Investor's Business Daily
MindMed Leverages Ayahuasca's Ingredient DMT In Psychedelic-Inspired Therapies, Launches Trials With 30 Subjects
Psychoactive brew ayahuasca is known for having a fast-onset antidepressant effect. With serotonergic psychedelics, such... 
Via Benzinga
Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To "Psychedelics Renaissance"
Excitement around psychedelics grows as major U.S. exchanges make room for more companies in the sector. On Friday, 
Via Benzinga
Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness
Via FinancialNewsMedia
Topics Law Enforcement
Exposures Legal
Mind Medicine Has More Obstacles Than Opportunities
MNMD stock could revolutionize mental healthcare with its novel therapeutics, but there are currently too many risks with its business. 
Via InvestorPlace
Psychedelic Decriminalization Creating Market Opportunities
Via FinancialNewsMedia
Topics Cannabis Law Enforcement
Exposures Cannabis Legal
Psyched: Numinus, MindMed, Cybin Reach Milestones, Harvard To Study Psychedelics Law, Michael Pollan Dives Into Mescaline
Michael Pollan’s New Book Takes A Deep Dive Into Mescaline – Will This Be A Turning Point For The Recognition And Study of&n... 
Via Benzinga
How To Invest In "Magic Mushrooms" (Psychedelics)
A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest. 
Via Talk Markets
MindMed Stock Is Overvalued and Too Risky to Own
MindMed can be the future of psychedelic medicines, but without cash flow from revenue, MNMD stock is nothing to get excited about. 
Via InvestorPlace
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Ps... 
Via Benzinga
The 6 Leading Psychedelic Stocks In Drug R&D
Drug R&D in the emerging psychedelic drug industry continues to advance. Share prices continue to lag. Here's a comparison of the strengths and weaknesses of six of the leaders in psychedelic drug R&D... 
Via Talk Markets
Rising Prevalence of Mental Depression & Anxiety Major Drivers Propelling Demand In Psychedelic Drugs Market
Via FinancialNewsMedia
Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential o... 
Via Benzinga
The MindMed Psychedelic Revolution Will Take Years to Come to Fruition
MNMD stock aspires to be a lot to many but could flop. Prices are low, risk is high and speculators could become savants. 
Via InvestorPlace
Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More
Institutional analysts are taking a liking to the industry ... 
Via Benzinga
Video: Talking Cannabis With Aurora Co-Founder Terry Booth | Benzinga Cannabis Insider 6/29
Benzinga’s 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Get a Dose of Innovative Science With Mind Medicine
MNMD stock ran high last year, but the story is still being written as Mind Medicine marks progress with its psychedelics-based treatments. 
Via InvestorPlace
Psychedelics-Focused MindMed Joins FTSE Russell 3000 Index, 'A True Honor'
A psychedelics-focused medicine company MindMed (NASDAQ: 
Via Benzinga
Pandemic Fallout: 6 Mental Health Stocks To Watch
One of the most devastating long-term impacts of the COVID-19 pandemic may be the toll it has taken on people’s mental health. The next globa... 
Via Benzinga
Exposures COVID-19
MindMed Can Play a Big Role in the Growing Mental Wellness Industry
With Covid-19 increasing the frequency of mental health problems, MNMD stock is a way to invest in psychedelics, which are seeing legitimacy. 
Via InvestorPlace
Exposures COVID-19
Why This MindMed Analyst Is Bullish: 'One Of The Most Diverse Pipelines In Psychedelics'
Mind Medicine (MindMed) Inc (NASDAQ:MNMD) shares traded hi... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2021
Upgrades For Toll Brothers Inc (NYSE: 
Via Benzinga
Cannabis Movers & Shakers: HempFusion, Decibel, ARCA, Love Hemp, MindMed, Halo
HempFusion Wellness Promotes VP And Controller Maria Leal To Interim CFO HempFusion Wellness Inc. (TSX: 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Atai IPO Day An Underwhelming Event
The IPO of atai Life Sciences was arguably the most-anticipated event in the emerging psychedelic drug industry. It failed to live up to expectations. 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
< Previous 1 2
...
26 27 28 29 30 31 32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.